+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

New oral anticoagulants for treatment of venous thromboembolism



New oral anticoagulants for treatment of venous thromboembolism



Deutsche Medizinische Wochenschrift 136(22): 1162-1164



In the current treatment of venous thromboembolism most patients are treated with vitamin K antagonists (VKA). VKA have many disadvantages including slow onset of action, multiple food and drug interactions and a large inter-individual variability in their efficacy. Recently several alternative oral anticoagulants have been developed, which have several advantages in comparison to VKA. So far two large randomized studies comparing new oral anticoagulants with VKA in patients with venous thromboembolism have been published: the RECOVER study with the oral direct thrombin antagonist dabigatran and the EINSTEIN-DVT study with the oral direct factor Xa-antagonist rivaroxaban. With regard to recurrent venous thromboembolism and bleeding complications, both drugs were comparable with VKA. In addition, two other studies are ongoing with the oral direct factor Xa antagonists apixaban and edoxaban for this indication. The final role of the new oral anticoagulants in the future treatment of venous thromboembolism has to be determined. However the first results from randomized trails are encouraging.

Accession: 054611196

Download citation: RISBibTeXText

PMID: 21611919

DOI: 10.1055/s-0031-1280530


Related references

New oral anticoagulants for the treatment of venous thromboembolism. Best Practice & Research. Clinical Haematology 26(2): 151-161, 2014

Oral anticoagulants for the treatment of venous thromboembolism. Bailliere's Clinical Haematology 11(3): 639-661, 1999

New oral anticoagulants in the treatment of venous thromboembolism. Presse Medicale 42(9 Pt 1): 1232-1238, 2013

New oral anticoagulants for the treatment ofA venous thromboembolism. 2013

Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism: A Systematic Review. Journal of Cardiovascular Pharmacology and Therapeutics 20(5): 490-500, 2016

Management of oral anticoagulants in the treatment of venous thromboembolism. European Journal of Internal Medicine 12(2): 75-85, 2001

Evolving use of new oral anticoagulants for treatment of venous thromboembolism. Blood 124(7): 1020-1028, 2015

Use of the Direct Oral Anticoagulants for the Treatment of Venous Thromboembolism. Hematology/Oncology Clinics of North America 30(5): 1035-1051, 2017

The treatment of cancer-associated venous thromboembolism in the era of the novel oral anticoagulants. Expert Opinion on PharmacoTherapy 16(16): 2391-2394, 2016

Direct oral anticoagulants for venous thromboembolism treatment and prophylaxis. Jaapa 29(8): 24-29, 2018

Treatment of venous thromboembolism with new oral anticoagulants according to patient risk. Seminars in Thrombosis and Hemostasis 41(2): 160-165, 2015

Direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism. Blood Research 49(2): 77-79, 2014

The place of novel oral anticoagulants in prevention and treatment of venous thromboembolism. Angiologiia i Sosudistaia Khirurgiia 20(3): 89-93, 2014

Prevention and treatment of venous thromboembolism: the place of new oral anticoagulants. Revista Portuguesa de Cardiologia 31 Suppl 1: 45-50, 2014

Clinical experience with the new oral anticoagulants for treatment of venous thromboembolism. Arteriosclerosis, Thrombosis, and Vascular Biology 35(3): 513-519, 2016